Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Phase III Trial Comparing Adjuvant Trastuzumab Plus Neratinib Versus Trastuzumab Plus Pertuzumab in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Residual Cancer Burden 0/I After Neoadjuvant Trastuzumab Plus Pertuzumab
Conditions
Interventions
Trastuzumab and neratinib
Trastuzumab and Pertuzumab
Locations
1
China
Sun Yat-sen University Sun Yat-sen Memorial Hospital
Guangzhou, China
Start Date
March 14, 2023
Primary Completion Date
February 16, 2028
Completion Date
November 1, 2028
Last Updated
September 25, 2025
NCT06949410
NCT06253871
NCT07459673
NCT07102381
NCT04585750
NCT04886531
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions